Dermatitis Program
Professor Chris Jackson's group at the University of Sydney has undertaken research on APC in chronic wound healing and inflammatory skin disorders for more than a decade and they have published over 60 relevant scientific papers in high impact journals. The following diagram demonstrates the multiple beneficial therapeutic effects of APC.
Standard topical treatment for dermatitis is corticosteroids; however, a serious side effect of prolonged use is permanent thinning of skin, which worsens the condition. In 2020, Professor Jackson's group completed a TR47 in dermatitis mouse study showing it to be as effective as corticosteroids, without the side effects.
Novapep has developed a topical gel with FDA approved excipients. Professor Jackson will undertake G10 dermatitis/burns studies in 2022.
Annual global sales of corticosteroids for dermatitis are ~$2.5 billion and Novapep is targeting a minimum 30% market share within the first three years of marketing approvals. The global market size for burns treatments is $2 billion and the second degree burns market segment is estimated to be one quarter of the total market.